Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,470.00
(
-1.06%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,641.58
(
0.18%
)
News Focus
News Focus
Post# of 257265
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 150873

Thursday, 10/18/2012 8:15:50 PM

Thursday, October 18, 2012 8:15:50 PM

Post# of 257265
Re: BCRX-Presidio merger

The latest info on Presidio’s PPI-668 (an NS5A inhibitor) are the 3-day monotherapy data reported in Jun 2012 (#msg-76993511).

I continue to maintain that BCRX’s nucleoside drug is based on obsolete and discredited technology (#msg-65152679).

All told, therefore, combining these two HCV drugs does not exactly seem like a winning formula for commercial success.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today